Skip to main content
Aelis Farma logo

Aelis Farma — Investor Relations & Filings

Ticker · AELIS ISIN · FR0014007ZB4 LEI · 8945008D5R6WV7EXRN47 PA Manufacturing
Open in API
Filings indexed 157 across all filing types
Latest filing 2022-07-06 Transaction in Own Shar…
Country FR France
Listing PA AELIS

About Aelis Farma

https://www.aelisfarma.com

Aelis Farma is a clinical-stage biopharmaceutical company that discovers and develops treatments for brain and central nervous system (CNS) disorders. The company has created a new class of drugs called Signaling Specific inhibitors of the CB1 receptor (CB1-SSi). This proprietary mechanism is designed to selectively inhibit the pathological signaling of the CB1 receptor, which is implicated in various brain diseases, while preserving its normal physiological functions and avoiding adverse effects associated with previous CB1-targeting drugs. The company's lead drug candidate, AEF0117, is in development for the treatment of Cannabis Use Disorder (CUD). Its second candidate, AEF0217, is being investigated for the treatment of cognitive deficits, including those associated with Down syndrome.

Recent filings

Filing Released Lang Actions
Informations privilégiées / Autres communiqués
Transaction in Own Shares Classification · 98% confidence The document is a press release dated July 6, 2022, titled "Bilan semestriel du contrat de liquidité contracté avec Natixis ODDO BHF" (Semi-annual report on the liquidity contract entered into with Natixis ODDO BHF). It details the activity (purchases and sales of shares) under a liquidity contract for the period from March 18, 2022, to June 30, 2022. This type of announcement, which reports on the execution of a specific financial arrangement (liquidity contract/share buyback program) over a defined period, is typically classified as a report on the company's own share transactions or capital structure changes. Since the document explicitly details the transactions in the company's own shares (purchases and sales) under a formal agreement, the most appropriate category is 'Transaction in Own Shares' (POS). It is not a comprehensive financial report (10-K or IR), nor is it a general earnings release (ER).
2022-07-06 French
Informations privilégiées / Autres communiqués
AGM Information Classification · 98% confidence The document is explicitly titled "Communiqué de presse" (Press Release) and announces the details for the upcoming "Assemblée générale ordinaire" (Ordinary General Meeting) scheduled for June 28, 2022. It details where the preparatory documents are available, how shareholders can participate (in person, by proxy, or by correspondence), and provides general company information. This content—announcing the logistics and availability of materials for a shareholder meeting—is characteristic of an AGM announcement or related preparatory material. Since the document itself is an announcement about the meeting and the availability of related documents, and not the voting results (DVA) or the formal proxy solicitation materials (PSI), the most fitting category is AGM Information (AGM-R), which covers presentations and materials shared during the AGM, or potentially a Report Publication Announcement (RPA) if it were purely a notice that materials were available. However, because the core subject is the AGM logistics and date, AGM-R is the primary classification. The document length (8277 chars) is substantial enough that it's more than just a brief notice, suggesting it contains substantive information about the meeting itself.
2022-06-07 French
Inside Information / Other news releases
AGM Information Classification · 98% confidence The document is explicitly titled as a 'Press release' and announces the details regarding the 'Ordinary General Meeting of June 28, 2022: Availability of preparatory documents and participation and voting procedures'. This content directly relates to the logistics, agenda, and documentation for an upcoming shareholder meeting. This aligns perfectly with the definition of AGM Information (AGM-R), which covers presentations and materials shared during the Annual General Meeting. Although it mentions the availability of documents, the primary focus is the meeting itself, making AGM-R more specific than a general Report Publication Announcement (RPA).
2022-06-07 English
Informations privilégiées / Autres communiqués
Regulatory Filings Classification · 95% confidence The document is titled 'Communiqué de presse' (Press Release) and announces a specific corporate event: the inclusion of the first patient in a Phase 2b clinical trial for the drug AEF0117. It details the trial design, expected results timeline (2024), partnership agreements (Indivior), and provides company background. This format—a formal announcement of a significant operational/clinical milestone, issued via press release—is characteristic of an Earnings Release (ER) or a general Regulatory Filing (RNS). Since it is not a full financial report (10-K, IR) or a transcript (CT), and it is a direct announcement of news rather than a notice about a report being published (RPA), the most appropriate classification is Earnings Release (ER) as it conveys key operational and financial news, or RNS as a general regulatory announcement. Given the focus on clinical trial progress and partnership milestones, which often accompany or substitute for quarterly earnings news in biotech, ER is a strong candidate, but RNS is the safest general regulatory announcement category for non-standard filings. However, since this is a major operational update presented as a press release, and it is not a formal financial report, it fits best under the general 'Regulatory Filings' (RNS) category, as it is a public disclosure of material information not covered by other specific codes like DIV, DIRS, or CAP. Given the options, RNS is the most encompassing fit for a general press release detailing clinical progress.
2022-06-01 French
Inside Information / Other news releases
Regulatory Filings Classification · 95% confidence The document is explicitly titled 'Press release' and announces a specific corporate event: the inclusion of the 1st patient in a Phase 2b study for drug candidate AEF0117. It details clinical trial progress, partnership milestones (with Indivior), and financial implications related to that progress. This content structure—a formal announcement of operational/clinical progress, often released to the market to inform investors—is characteristic of an Earnings Release (ER) or a general Regulatory Filing (RNS). Since it is not a full financial report (10-K, IR), a transcript (CT), or a specific management/board change announcement (MANG), and it is a direct announcement of operational news rather than just announcing a report's publication (RPA), the most fitting category is Earnings Release (ER) as it conveys key performance/progress updates, or RNS as a general regulatory announcement. Given the focus on clinical milestones and partnership value updates, ER is often used for such operational highlights, but RNS is the safest fallback for non-standard announcements. However, since it is a press release detailing significant operational progress and financial updates related to development, it aligns closely with the function of an Earnings Release (ER) which communicates key period results/updates, even if not strictly quarterly financials. If we consider the definitions, it is a specific operational update, not a general regulatory filing. Let's re-evaluate against the options. It is not a 10-K, AR, CT, MANG, DVA, DLST, DIRS, SR, XLSX, FS, CGR, IRAT, IR, IP, LTR, TAR, MRQ, NAV, DIV, PSI, DEF 14A, RPA, SHA, or POS. It is a press release announcing progress, which often falls under ER or RNS. Given the detailed operational and financial milestone reporting, ER is a strong candidate, but RNS is the general catch-all for press releases not fitting elsewhere. Since it is a press release announcing a major clinical milestone and associated financial terms, it functions as a key operational update, which often substitutes for or accompanies an ER in biotech. I will classify it as RNS as it is a general press release announcement not strictly matching the definition of ER (which usually implies financial results highlights).
2022-06-01 English
Rapports financiers et d'audit annuels: Rapport financier annuel
Annual Report Classification · 100% confidence The document is titled 'RAPPORT FINANCIER ANNUEL 2021' (Annual Financial Report 2021) for Aelis Farma SA. It contains comprehensive financial statements, management reports, governance information, and audit reports for the fiscal year ending December 31, 2021. It is a full annual report, not an announcement or a summary, and it includes detailed financial data and analysis. FY 2021
2022-04-27 French

Browse filings by year

5 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.